Header

UZH-Logo

Maintenance Infos

The Use of Photon Beams of a Flattening Filter-free Linear Accelerator for Hypofractionated Volumetric Modulated Arc Therapy in Localized Prostate Cancer


Zwahlen, Daniel R; Lang, Stephanie; Hrbacek, Jan; Glanzmann, Christoph; Kloeck, Stephan; Najafi, Yousef; Streller, Tino; Studer, Gabriela; Zaugg, Kathrin; Luetolf, Urs M (2012). The Use of Photon Beams of a Flattening Filter-free Linear Accelerator for Hypofractionated Volumetric Modulated Arc Therapy in Localized Prostate Cancer. International Journal of Radiation Oncology, Biology and Physics, 83(5):1655-1660.

Abstract

PURPOSE: To evaluate the potential usage of flattening filter-free (FFF) photon beams in the treatment of prostate cancer.

METHODS AND MATERIALS: Volumetric-modulated arc therapy (VMAT) treatment planning was performed for 7 patients using TrueBeam(®) linear accelerator and photon beams with (X6, X10) and without (X6FFF, X10FFF) flattening filter. Prescribed dose was 19 × 3 Gy = 57 Gy. One or two 360° arcs with dose rate of 600 MU/min for flattened beams, and 1,200 MU/min for FFF beams were used.

RESULTS: No difference was detected between the four beams in PTV coverage, conformity, and homogeneity. Mean body dose and body volume receiving 50% of the prescribed dose decreased with increasing mean energy (r(2) = 0.8275, p < 0.01). X6FFF delivered 3.6% more dose compared with the X6 (p < 0.01). X10FFF delivered 3.0% (p < 0.01), and the X10 5.8% (p < 0.01) less mean body dose compared with X6. There was a significant increase in the mean dose to the rectum for the X10 compared with X6 (2.6%, p < 0.01). Mean dose to the bladder increased by 1.3% for X6FFF and decreased by 2.3% for X10FFF. Using a single arc and FFF, treatment time was reduced by 35% (2 SD = 10%).

CONCLUSION: FFF beams resulted in dose distributions similar to flattened beams. X10FFF beam provided the best solution, sparing rectum and bladder and minimizing whole-body dose. FFF beams lead to a time efficient treatment delivery, particularly when combined with hypofractionated VMAT.

Abstract

PURPOSE: To evaluate the potential usage of flattening filter-free (FFF) photon beams in the treatment of prostate cancer.

METHODS AND MATERIALS: Volumetric-modulated arc therapy (VMAT) treatment planning was performed for 7 patients using TrueBeam(®) linear accelerator and photon beams with (X6, X10) and without (X6FFF, X10FFF) flattening filter. Prescribed dose was 19 × 3 Gy = 57 Gy. One or two 360° arcs with dose rate of 600 MU/min for flattened beams, and 1,200 MU/min for FFF beams were used.

RESULTS: No difference was detected between the four beams in PTV coverage, conformity, and homogeneity. Mean body dose and body volume receiving 50% of the prescribed dose decreased with increasing mean energy (r(2) = 0.8275, p < 0.01). X6FFF delivered 3.6% more dose compared with the X6 (p < 0.01). X10FFF delivered 3.0% (p < 0.01), and the X10 5.8% (p < 0.01) less mean body dose compared with X6. There was a significant increase in the mean dose to the rectum for the X10 compared with X6 (2.6%, p < 0.01). Mean dose to the bladder increased by 1.3% for X6FFF and decreased by 2.3% for X10FFF. Using a single arc and FFF, treatment time was reduced by 35% (2 SD = 10%).

CONCLUSION: FFF beams resulted in dose distributions similar to flattened beams. X10FFF beam provided the best solution, sparing rectum and bladder and minimizing whole-body dose. FFF beams lead to a time efficient treatment delivery, particularly when combined with hypofractionated VMAT.

Statistics

Citations

32 citations in Web of Science®
30 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

4 downloads since deposited on 19 Jul 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, not refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:19 Jul 2012 14:52
Last Modified:07 Dec 2017 14:36
Publisher:Elsevier
ISSN:0360-3016
Publisher DOI:https://doi.org/10.1016/j.ijrobp.2011.10.019
PubMed ID:22572080

Download